Posted by Michael Wonder on 10 Aug 2021
Dermavant announces FDA acceptance for filing of new drug application for tapinarof cream for the treatment of adults with plaque psoriasis
10 August 2021 - FDA PDUFA action expected in Q2 2022.
Dermavant Sciences today announced that the U.S. FDA accepted for filing the company’s new drug application for tapinarof for the treatment of plaque psoriasis in adult patients.
